The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Trump Declares National Emergency on Opioid Abuse

Trump Declares National Emergency on Opioid Abuse

August 10, 2017 • By James Oliphant

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BEDMINSTER, N.J. (Reuters)—U.S. President Donald Trump on Thursday declared the opioid epidemic a national emergency and said his administration was drafting papers to make it official.

You Might Also Like
  • Trump Declares Opioids a U.S. Public Health Emergency
  • Trump Panel Urges More Treatment Options to Fight Opioid Crisis
  • U.S. Life Expectancy Fell in 2016 as Opioid Overdoses Surged—CDC
Also By This Author
  • McCain to Return for Pivotal U.S. Senate vote on Healthcare

“The opioid crisis is an emergency and I’m saying officially right now it is an emergency,” Trump told reporters in New Jersey. “We’re going to draw it up and we’re going to make it a national emergency. It is a serious problem, the likes of which we have never had.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Trump spoke about a week after a White House commission on the opioid crisis led by New Jersey Governor Chris Christie recommended the president declare it a national emergency.

The declaration could help unlock more support and resources to address the drug overdose epidemic, such as additional funding and expanded access to various forms of treatment, and it gives the government more flexibility in waiving rules and restrictions to expedite action.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

National emergencies are typically declared for short-term crises, such as the Zika virus outbreak or a natural disaster. It is unclear what Trump’s declaration will mean for a complex, long-term public health problem.

“We’re going to spend a lot of time, a lot of effort and a lot of money on the opioid crisis,” Trump said. “This is a worldwide problem, not just a United States problem.”

More than 100 Americans die of drug overdoses every day, the commission wrote in a report, noting that “America is enduring a death toll equal to September 11th every three weeks.” Opioids played a role in more than 33,000 deaths in 2015, according to the U.S. Centers for Disease Control and Prevention.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Trump held a “major briefing” on the epidemic on Tuesday, but stopped short of following the commission’s recommendation. Instead, he talked mostly about stopping the flow of drugs into the United States and ensuring young people never start using drugs. He did not discuss access to treatment.

 

Filed Under: Drug Updates Tagged With: national emergency, opioid crisis, opioid epidemic

You Might Also Like:
  • Trump Declares Opioids a U.S. Public Health Emergency
  • Trump Panel Urges More Treatment Options to Fight Opioid Crisis
  • U.S. Life Expectancy Fell in 2016 as Opioid Overdoses Surged—CDC
  • New Jersey Sues OxyContin Maker, Links Marketing to Opioid Crisis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)